Display Settings:


Send to:

Choose Destination

Drug treatments for the prevention of migraine headache

Gray, Rebecca N
United States Agency for Health Care Policy and Research
Duke University Center for Clinical Health Policy Research
Drug treatments for the prevention of migraine headache [electronic resource] / prepared for Agency for Health Care Policy and Research, Department of Health and Human Services, U.S. Public Health Service ; prepared by Center for Clinical Health Policy Research, Duke University ; contributing authors, Rebecca N. Gray ... [et al.].
Technical review ; 2.3
Country of Publication:
United States
Rockville, MD : Agency for Health Care Policy and Research, 1999.
1 online resource (1 PDF file (v, 421 p.)).
Electronic Links:
OBJECTIVES: To identify and summarize evidence from controlled trials on the efficacy and tolerability of drug treatments for the prevention of migraine. SEARCH STRATEGY: A strategy combining the MeSH term "headache" (exploded) and a previously published strategy for identifying randomized controlled trials were used on the January 1966 to December 1996 MEDLINE database. Other computerized bibliographic databases, textbooks, and experts were also utilized. SELECTION CRITERIA: We selected English-language controlled trials involving patients with migraine headache in which at least one treatment offered was a drug given regularly during headache-free intervals with the aim of preventing the occurrence of migraine attacks. DATA COLLECTION AND ANALYSIS: Measures of headache index and headache frequency reported as group means (and standard deviations) were used to calculate standardized mean differences (or effect sizes). The number of patients obtaining at least a 50% reduction in headache index, frequency, or severity was recorded and used to calculate odds ratios. Where similar trials provided data, meta-analysis of efficacy measures was performed. The identity and rates of adverse events were recorded and statistically compared. MAIN RESULTS: Placebo-controlled trials support the efficacy of several drugs for the prevention of migraine. Drugs with multiple placebo-controlled trials suggesting at least moderate efficacy include: propranolol (effect size, 0.55; 95% confidence interval, 0.42 to 0.69), timolol (0.69; 0.18 to 1.2), sodium valproate and divalproex sodium (0.93; 0.39 to 1.5), naproxen sodium (0.29; 0.01 to 0.57), amitriptyline (0.62; 0.15 to 1.1), methysergide (no effect size estimate), flunarizine (0.52; 0.24 to 0.80), pizotifen (0.91; 0.50 to 1.3), and lisuride (no effect size estimate). Other beta-blockers demonstrated efficacy similar to that of propranolol, except for those with intrinsic sympathomimetic activity, which did not appear to be efficacious. Within other, more diverse drug categories -- such as antidepressants, calcium antagonists, and anticonvulsants -- there was more variability in the efficacy of different agents. Except for the comparison of propranolol with flunarizine, equivalence has not been demonstrated among the various agents found to be efficacious in placebo-controlled trials. Many efficacious preventive drugs were poorly tolerated in the reviewed trials and were associated with substantial rates of patient withdrawals. CONCLUSIONS: Several specific agents have been shown to be efficacious for the prevention of migraine; however, there are few data to guide the choice among agents, and poor tolerability and lack of availability in the U.S. limit the usefulness of many of the drugs reviewed.
Controlled Clinical Trials as Topic
Evidence-Based Medicine
Meta-Analysis as Topic
Migraine Disorders/drug therapy*
Migraine Disorders/prevention & control*
Treatment Outcome
Title from PDF t.p.
"February 1999."
Includes bibliographical references.
Also issued in print.
Contract No. 290-94-2025.
Mode of access: Internet.
101554787 [Electronic Resource]

Supplemental Content

Loading ...
Write to the Help Desk